• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Pregnancy and Postpartum Course
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Pregnancy and Postpartum Course
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » Buprenorphine Induction Using Long-Acting Injection
Research Update

Buprenorphine Induction Using Long-Acting Injection

July 1, 2025
Noah Capurso, MD, MHS
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Noah Capurso, MD, MHS. Dr. Capurso has no financial relationships with companies related to this material.

Getting your Trinity Audio player ready...
REVIEW OF: D’Onofrio G et al, JAMA Netw Open 2024;7(7):e2420702


STUDY TYPE: Nonrandomized prospective feasibility trial

Clinicians managing opioid use disorder (OUD) face a common clinical challenge: Patients need to be in moderate opioid withdrawal before starting buprenorphine to avoid precipitated withdrawal (for more on the induction process with sublingual [SL] buprenorphine, see CATR Nov/Dec 2021). This requirement can create a significant barrier to treatment, especially in the emergency department (ED) and other acute care settings where extended observation is not practical. The challenge has become even greater with the increased prevalence of illicit fentanyl, which now dominates the drug supply and carries a higher risk of precipitated withdrawal.

Could long-acting injectable buprenorphine provide a solution? The theory makes sense—injectables reach peak serum levels more slowly than SL formulations (24 hours versus 1 hour for SL), potentially allowing earlier administration with lower risk of precipitated withdrawal.

To test this approach, researchers recruited 100 adults with OUD who were being treated in the ED for opioid use. They all had minimal withdrawal symptoms (Clinical Opiate Withdrawal Scale [COWS] score <8) and therefore were not yet eligible to receive SL buprenorphine. Instead of waiting for moderate withdrawal, researchers gave participants a 24 mg injection of weekly extended-release buprenorphine (Brixadi). Patients were monitored for four hours post-injection for precipitated withdrawal and subsequently followed daily for seven days.

The results were promising. Only 7% of participants experienced precipitated withdrawal within 4 hours, comparable to rates seen with standard SL induction (Gregory C et al, Addiction 2025;120(1):7–20). Notably, the percentage of participants who developed precipitated withdrawal varied significantly based on starting COWS scores: 13.5% in those with very low scores (0–3) versus just 3.2% in those with scores of 4–7. The incidents of precipitated withdrawal, as well as a single instance of nausea and vomiting, were the only adverse effects attributed to the medication.

Participants also generally did well in follow-up. Most (78%–85%) reported no opioid use on any given day during the week following injection, and 60% remained completely abstinent throughout the follow-up period. By day 7 after the injection, 73% of participants had engaged in ongoing OUD treatment and were receiving some form of buprenorphine.

Though the results seem promising, note that this was a small non-blinded study without a control group conducted in a single ED. Further studies will have to be performed in order to determine the generalizability of these results. 

CARLAT TAKE 
This study shows that injectable buprenorphine can be used to initiate treatment for OUD with minimal risk of precipitated withdrawal. More research is needed before this approach becomes standard practice, and the cost of injectable formulations remains a barrier. Nonetheless, consider this strategy for patients using fentanyl who are otherwise difficult to engage or very sensitive to withdrawal, especially if they present to acute settings with mild symptoms of withdrawal (COWS 4–7).

Addiction Treatment
KEYWORDS buprenorphine buprenorphine induction LAI long acting injectable medication for opioid use disorder opioid use disorder
    Ncapurso
    Noah Capurso, MD, MHS

    Brixadi: A New Long-Acting Buprenorphine Option for Opioid Use Disorder

    More from this author
    www.thecarlatreport.com
    Issue Date: July 1, 2025
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Psychotherapy For Addiction, CATR, July/August/September 2025
    Note From the Editor-in-Chief
    Substance Use Disorder Treatment: Medication or Psychotherapy?
    Motivational Interviewing
    Supporting Sobriety With 12-Step Facilitation
    Brixadi: A New Long-Acting Buprenorphine Option for Opioid Use Disorder
    Buprenorphine Induction Using Long-Acting Injection
    Starting Long-Acting Buprenorphine During Medical Hospitalization
    CME Post-Test, Psychotherapy For Addiction, CATR, July/August/September 2025
    DOWNLOAD NOW
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2637648401.jpg
      General Psychiatry

      Psychopharm Secrets: Coming Off Meds

      There’s a hidden placebo response to watch for when patients stop meds on their own.
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.